This ExpertREACT article was originally published on 2 July 2008 following the XVII Lancefield International Symposium in Porto Heli, Greece. Conference presentations and scientific data described reflect the state of knowledge at that date.
GAS: a globally important pathogen
Group A Streptococcus (GAS, Streptococcus pyogenes) is a Gram-positive bacterium usually colonising the human throat and skin without consequence but also one of the world's most frequent human pathogens - often placed alongside HIV, malaria and tuberculosis in terms of global disease burden. GAS causes a range of diseases from mild pharyngitis ("strep throat") and impetigo to severe life-threatening invasive disease including Streptococcal Toxic Shock Syndrome (STSS, mortality >35%) and necrotising fasciitis ("flesh-eating disease", mortality >50%). In the US, GAS is estimated to cause 9,000-11,000 cases of invasive disease annually and approximately 15 million cases of pharyngitis (CDC figures). Post-infection sequelae include rheumatic heart disease (RHD) and post-streptococcal glomerulonephritis, with WHO estimating 15.6 million existing RHD cases, 282,000 new cases and approximately as many deaths per year - predominantly in developing countries.
The virulence of GAS is related to an elaborate array of bacterial surface molecules including the M-protein (emm), of which there are over 100 serotypes - creating a significant vaccine development challenge. Early work by Rebecca Lancefield demonstrated that GAS strains rich in M-protein were more virulent, and M-protein has since remained the central focus of vaccine development efforts. However, the diversity of M-protein types means that a vaccine would need to either cover a very broad range of serotypes or exploit a conserved GAS antigen, both of which present formidable scientific challenges.
Clinical trial design challenges
The XVII Lancefield meeting reinforced that beyond the antigenic complexity, the path to a GAS vaccine was also complicated by clinical trial endpoint design. Defining and measuring protection against GAS pharyngitis - a self-limiting condition in most individuals - versus invasive disease (rarer but severe) versus RHD prevention (a post-infectious complication) required fundamentally different study designs, population sizes and time horizons. VacZine Analytics concluded that GAS vaccine development would require concerted academic and industry collaboration to define viable regulatory pathways, and that R&D capacity limitations - with few commercial companies actively pursuing GAS - remained the primary constraint on progress.